The safety and tolerability of darbepoetin alfa in patients with anaemia and symptomatic heart failure

Marc Klapholz, William T. Abraham, Jalal K. Ghali, Piotr Ponikowski, Stefan D. Anker, Beat Knusel, Yan Sun, Scott M. Wasserman, Dirk J. Van Veldhuisen

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Aims To assess the safety and tolerability of darbepoetin alfa (DA) in the treatment of anaemia in heart failure (HF).Methods and resultsIn this pooled analysis of three randomized, double-blind, placebo-controlled studies of anaemic [haemoglobin (Hb) ≤12.0 g/dL or ≤12.5 g/dL] symptomatic HF subjects, DA was administered subcutaneously once every 2 weeks and titrated to achieve and maintain a target Hb of 14.0 ± 1.0 g/dL. In total, 516 subjects were randomized; 231 (44.8) to placebo, 285 (55.2) to DA. Darbepoetin alfa was well tolerated, with an adverse event (AE) profile similar to placebo. Most subjects (placebo, 85; DA, 87) experienced at least one AE. There was a lower incidence of serious AEs in the DA group (placebo, 43; DA, 37) with the most frequent being worsening HF (placebo, 19; DA, 11). Treatment-related AEs were reported for 9 and 12 in placebo and DA subjects, respectively. Fewer deaths were reported in DA group (6) vs. placebo (8).ConclusionDarbepoetin alfa was well tolerated with an AE profile similar to placebo in HF subjects treated to a target Hb of 14.0 ± 1.0 g/dL. Contrary to recent data in other patient populations, there was no evidence of increased risk of mortality or cardiovascular events.

Original languageEnglish
Pages (from-to)1071-1077
Number of pages7
JournalEuropean Journal of Heart Failure
Volume11
Issue number11
DOIs
Publication statusPublished - Nov 2009

Fingerprint

Anemia
Heart Failure
Placebos
Safety
Hemoglobins
Darbepoetin alfa
Mortality
Incidence
Therapeutics
Population

Keywords

  • Anaemia
  • Haemoglobin
  • Heart failure
  • Kidney
  • Mortality

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Klapholz, M., Abraham, W. T., Ghali, J. K., Ponikowski, P., Anker, S. D., Knusel, B., ... Van Veldhuisen, D. J. (2009). The safety and tolerability of darbepoetin alfa in patients with anaemia and symptomatic heart failure. European Journal of Heart Failure, 11(11), 1071-1077. https://doi.org/10.1093/eurjhf/hfp130

The safety and tolerability of darbepoetin alfa in patients with anaemia and symptomatic heart failure. / Klapholz, Marc; Abraham, William T.; Ghali, Jalal K.; Ponikowski, Piotr; Anker, Stefan D.; Knusel, Beat; Sun, Yan; Wasserman, Scott M.; Van Veldhuisen, Dirk J.

In: European Journal of Heart Failure, Vol. 11, No. 11, 11.2009, p. 1071-1077.

Research output: Contribution to journalArticle

Klapholz, M, Abraham, WT, Ghali, JK, Ponikowski, P, Anker, SD, Knusel, B, Sun, Y, Wasserman, SM & Van Veldhuisen, DJ 2009, 'The safety and tolerability of darbepoetin alfa in patients with anaemia and symptomatic heart failure', European Journal of Heart Failure, vol. 11, no. 11, pp. 1071-1077. https://doi.org/10.1093/eurjhf/hfp130
Klapholz, Marc ; Abraham, William T. ; Ghali, Jalal K. ; Ponikowski, Piotr ; Anker, Stefan D. ; Knusel, Beat ; Sun, Yan ; Wasserman, Scott M. ; Van Veldhuisen, Dirk J. / The safety and tolerability of darbepoetin alfa in patients with anaemia and symptomatic heart failure. In: European Journal of Heart Failure. 2009 ; Vol. 11, No. 11. pp. 1071-1077.
@article{752764f6849f4e53bcf40b3e09e1954b,
title = "The safety and tolerability of darbepoetin alfa in patients with anaemia and symptomatic heart failure",
abstract = "Aims To assess the safety and tolerability of darbepoetin alfa (DA) in the treatment of anaemia in heart failure (HF).Methods and resultsIn this pooled analysis of three randomized, double-blind, placebo-controlled studies of anaemic [haemoglobin (Hb) ≤12.0 g/dL or ≤12.5 g/dL] symptomatic HF subjects, DA was administered subcutaneously once every 2 weeks and titrated to achieve and maintain a target Hb of 14.0 ± 1.0 g/dL. In total, 516 subjects were randomized; 231 (44.8) to placebo, 285 (55.2) to DA. Darbepoetin alfa was well tolerated, with an adverse event (AE) profile similar to placebo. Most subjects (placebo, 85; DA, 87) experienced at least one AE. There was a lower incidence of serious AEs in the DA group (placebo, 43; DA, 37) with the most frequent being worsening HF (placebo, 19; DA, 11). Treatment-related AEs were reported for 9 and 12 in placebo and DA subjects, respectively. Fewer deaths were reported in DA group (6) vs. placebo (8).ConclusionDarbepoetin alfa was well tolerated with an AE profile similar to placebo in HF subjects treated to a target Hb of 14.0 ± 1.0 g/dL. Contrary to recent data in other patient populations, there was no evidence of increased risk of mortality or cardiovascular events.",
keywords = "Anaemia, Haemoglobin, Heart failure, Kidney, Mortality",
author = "Marc Klapholz and Abraham, {William T.} and Ghali, {Jalal K.} and Piotr Ponikowski and Anker, {Stefan D.} and Beat Knusel and Yan Sun and Wasserman, {Scott M.} and {Van Veldhuisen}, {Dirk J.}",
year = "2009",
month = "11",
doi = "10.1093/eurjhf/hfp130",
language = "English",
volume = "11",
pages = "1071--1077",
journal = "European Journal of Heart Failure",
issn = "1388-9842",
publisher = "John Wiley & Sons, Ltd",
number = "11",

}

TY - JOUR

T1 - The safety and tolerability of darbepoetin alfa in patients with anaemia and symptomatic heart failure

AU - Klapholz, Marc

AU - Abraham, William T.

AU - Ghali, Jalal K.

AU - Ponikowski, Piotr

AU - Anker, Stefan D.

AU - Knusel, Beat

AU - Sun, Yan

AU - Wasserman, Scott M.

AU - Van Veldhuisen, Dirk J.

PY - 2009/11

Y1 - 2009/11

N2 - Aims To assess the safety and tolerability of darbepoetin alfa (DA) in the treatment of anaemia in heart failure (HF).Methods and resultsIn this pooled analysis of three randomized, double-blind, placebo-controlled studies of anaemic [haemoglobin (Hb) ≤12.0 g/dL or ≤12.5 g/dL] symptomatic HF subjects, DA was administered subcutaneously once every 2 weeks and titrated to achieve and maintain a target Hb of 14.0 ± 1.0 g/dL. In total, 516 subjects were randomized; 231 (44.8) to placebo, 285 (55.2) to DA. Darbepoetin alfa was well tolerated, with an adverse event (AE) profile similar to placebo. Most subjects (placebo, 85; DA, 87) experienced at least one AE. There was a lower incidence of serious AEs in the DA group (placebo, 43; DA, 37) with the most frequent being worsening HF (placebo, 19; DA, 11). Treatment-related AEs were reported for 9 and 12 in placebo and DA subjects, respectively. Fewer deaths were reported in DA group (6) vs. placebo (8).ConclusionDarbepoetin alfa was well tolerated with an AE profile similar to placebo in HF subjects treated to a target Hb of 14.0 ± 1.0 g/dL. Contrary to recent data in other patient populations, there was no evidence of increased risk of mortality or cardiovascular events.

AB - Aims To assess the safety and tolerability of darbepoetin alfa (DA) in the treatment of anaemia in heart failure (HF).Methods and resultsIn this pooled analysis of three randomized, double-blind, placebo-controlled studies of anaemic [haemoglobin (Hb) ≤12.0 g/dL or ≤12.5 g/dL] symptomatic HF subjects, DA was administered subcutaneously once every 2 weeks and titrated to achieve and maintain a target Hb of 14.0 ± 1.0 g/dL. In total, 516 subjects were randomized; 231 (44.8) to placebo, 285 (55.2) to DA. Darbepoetin alfa was well tolerated, with an adverse event (AE) profile similar to placebo. Most subjects (placebo, 85; DA, 87) experienced at least one AE. There was a lower incidence of serious AEs in the DA group (placebo, 43; DA, 37) with the most frequent being worsening HF (placebo, 19; DA, 11). Treatment-related AEs were reported for 9 and 12 in placebo and DA subjects, respectively. Fewer deaths were reported in DA group (6) vs. placebo (8).ConclusionDarbepoetin alfa was well tolerated with an AE profile similar to placebo in HF subjects treated to a target Hb of 14.0 ± 1.0 g/dL. Contrary to recent data in other patient populations, there was no evidence of increased risk of mortality or cardiovascular events.

KW - Anaemia

KW - Haemoglobin

KW - Heart failure

KW - Kidney

KW - Mortality

UR - http://www.scopus.com/inward/record.url?scp=71049164279&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=71049164279&partnerID=8YFLogxK

U2 - 10.1093/eurjhf/hfp130

DO - 10.1093/eurjhf/hfp130

M3 - Article

C2 - 19815661

AN - SCOPUS:71049164279

VL - 11

SP - 1071

EP - 1077

JO - European Journal of Heart Failure

JF - European Journal of Heart Failure

SN - 1388-9842

IS - 11

ER -